{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:49:25Z","timestamp":1783694965240,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program, National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23053390-01A1"],"award-info":[{"award-number":["K23053390-01A1"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program, National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA55130"],"award-info":[{"award-number":["K01DA55130"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program, National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["SBIR 1R44DA050354-02"],"award-info":[{"award-number":["SBIR 1R44DA050354-02"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program, National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA015815"],"award-info":[{"award-number":["UG1DA015815"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024031","name":"Agency for Healthcare Research and Quality Safety Program for Telemedicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K12 HS026370"],"award-info":[{"award-number":["K12 HS026370"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.josat.2024.209511","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T20:05:52Z","timestamp":1725653152000},"page":"209511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis"],"prefix":"10.1016","volume":"167","author":[{"given":"Brian","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Levander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Wiest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie","family":"Pertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritwika","family":"Petluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.josat.2024.209511_bb0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1037\/fsh0000619","article-title":"Tier-based treatment for opioid use disorder in the primary care setting","volume":"39","author":"Angier","year":"2021","journal-title":"Families, Systems & Health"},{"issue":"8","key":"10.1016\/j.josat.2024.209511_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.28627","article-title":"Integrating opioid use disorder treatment into primary care settings","volume":"6","author":"Austin","year":"2023","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2024.209511_bb0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13722-022-00331-4","article-title":"Patient evaluation of a smartphone application for telehealth care of opioid use disorder","volume":"17","author":"Bosse","year":"2022","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2024.209511_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109057","article-title":"Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS","volume":"229","author":"Boyett","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2024.209511_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108444","article-title":"Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects","volume":"131","author":"Buchheit","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.josat.2024.209511_bb0030","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jsat.2012.07.013","article-title":"Development and initial evaluation of the Brief Addiction Monitor (BAM)","volume":"44","author":"Cacciola","year":"2013","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2024.209511_bb0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/08897077.2021.1967836","article-title":"Opioid treatment programs, telemedicine and COVID-19: A scoping review","volume":"43","author":"Chan","year":"2022","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.josat.2024.209511_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PRA.0000000000000437","article-title":"Availability of buprenorphine treatment in the 10 states with the highest drug overdose death rates in the United States","volume":"26","author":"Flavin","year":"2020","journal-title":"Journal of Psychiatric Practice"},{"issue":"10","key":"10.1016\/j.josat.2024.209511_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.36298","article-title":"Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic","volume":"5","author":"Frost","year":"2022","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2024.209511_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20177","article-title":"Treatment of opioid use disorder in pregnant women via telemedicine: A nonrandomized controlled trial","volume":"3","author":"Guille","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2024.209511_bb0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.52381","article-title":"Telemedicine use and quality of opioid use disorder treatment in the US during the COVID-19 pandemic","volume":"6","author":"Hailu","year":"2023","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.josat.2024.209511_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"8","key":"10.1016\/j.josat.2024.209511_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Network Open"},{"issue":"10","key":"10.1016\/j.josat.2024.209511_bb0070","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2024.209511_bb0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsat.2018.07.008","article-title":"Comparison between buprenorphine provider availability and opioid deaths among US counties","volume":"93","author":"Jones","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209511_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019\u2033","volume":"110","author":"Krawczyk","year":"2022","journal-title":"International Journal of Drug Policy"},{"issue":"4","key":"10.1016\/j.josat.2024.209511_bb0085","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11606-022-07905-7","article-title":"An urgent need for guidelines for telemedicine use","volume":"38","author":"Lin","year":"2023","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2024.209511_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108492","article-title":"Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder","volume":"133","author":"Lin","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.josat.2024.209511_bb0095","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/add.13270","article-title":"Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization","volume":"111","author":"Lo-Ciganic","year":"2016","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.josat.2024.209511_bb0100","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/M18-1652","article-title":"The next stage of buprenorphine care for opioid use disorder","volume":"169","author":"Martin","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.josat.2024.209511_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5195\/ijt.2016.6196","article-title":"Development of the Telehealth Usability Questionnaire (TUQ)","volume":"8","author":"Parmanto","year":"2016","journal-title":"International Journal of Telerehabilitation"},{"key":"10.1016\/j.josat.2024.209511_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.101043","article-title":"Recruitment challenges for a prospective telehealth cohort study","volume":"31","author":"Pertl","year":"2023","journal-title":"Contemporary Clinical Trials Communications"},{"key":"10.1016\/j.josat.2024.209511_bb0115","author":"Pharmacotherapy for Opioid Use Disorder [HEDIS Measures and Technical Resources]. NCQA"},{"key":"10.1016\/j.josat.2024.209511_bb0120","author":"Practice of Telemedicine: Listening Sessions. Federal Register.In: Administration. DE, Editor"},{"issue":"1","key":"10.1016\/j.josat.2024.209511_bb0125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/08897077.2021.1986882","article-title":"A bridge too far? Distance to waivered physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid","volume":"43","author":"Saloner","year":"2022","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2024.209511_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.josat.2024.209511_bb0135","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s11606-021-07249-8","article-title":"Buprenorphine telehealth treatment initiation and follow-up during COVID-19","volume":"37","author":"Samuels","year":"2022","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1016\/j.josat.2024.209511_bb0140","doi-asserted-by":"crossref","DOI":"10.2196\/23176","article-title":"Disparities in video and telephone visits among older adults during the COVID-19 pandemic: Cross-sectional analysis","volume":"3","author":"Schifeling","year":"2020","journal-title":"JMIR Aging"},{"issue":"5","key":"10.1016\/j.josat.2024.209511_bb0145","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009","volume":"103","author":"Schwartz","year":"2013","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.josat.2024.209511_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108314","article-title":"Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance","volume":"216","author":"Shover","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.josat.2024.209511_bb0155","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/ADM.0000000000000943","article-title":"Barriers to engagement in opioid use disorder treatment after buprenorphine induction","volume":"16","author":"Simpson","year":"2022","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.josat.2024.209511_bb0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A Plea from people who use drugs to clinicians: New ways to initiate buprenorphine are urgently needed in the fentanyl era","volume":"16","author":"Sue","year":"2022","journal-title":"Journal of Addiction Medicine"},{"issue":"2","key":"10.1016\/j.josat.2024.209511_bb0165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: Assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatric Services"},{"issue":"1","key":"10.1016\/j.josat.2024.209511_bb0170","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/ADM.0000000000000809","article-title":"A telemedicine buprenorphine clinic to serve New York City: Initial evaluation of the NYC public hospital system\u2019s initiative to expand treatment access during the COVID-19 pandemic","volume":"16","author":"Tofighi","year":"2022","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2024.209511_bb0175","series-title":"Time for the DEA to implement a special registration process for telemedicine prescribing of buprenorphine [dataset]","author":"Uscher-Pines","year":"2023"},{"issue":"14","key":"10.1016\/j.josat.2024.209511_bb0180","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMp1917360","article-title":"Stigma and the Toll of addiction","volume":"382","author":"Volkow","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.josat.2024.209511_bb0185","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.josat.2024.209511_bb0190","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s11606-022-07955-x","article-title":"A virtual-first telehealth treatment model for opioid use disorder","volume":"38","author":"Williams","year":"2023","journal-title":"Journal of General Internal Medicine"},{"issue":"6","key":"10.1016\/j.josat.2024.209511_bb0195","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1176\/appi.ajp.20220456","article-title":"Performance measurement for opioid use disorder medication treatment and care retention","volume":"180","author":"Williams","year":"2023","journal-title":"American Journal of Psychiatry"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924002236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924002236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T06:14:24Z","timestamp":1730614464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924002236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"alternative-id":["S2949875924002236"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209511","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209511"}}